Aktuelle Drittmittel
DFG Einzelprojekt - Multi-omics approach including structural variations in the genome of medulloblastoma to detect novel targets
Laufzeit: 2022-2024
Info: https://gepris-extern.dfg.de/gepris/projekt/497790467
DKTK Joint Funding Projekt LeOPARD - Rapid liquid biopsy and intraoperative diagnostics
Laufzeit: 2024 - 2026
Info: https://dktk.dkfz.de/en/research/joint-funding-projects/projects/details/62/7375
DKTK Joint Funding Projekt TRUST - Translational program of IT-PD1/NOA-26 study
Laufzeit: 2024 - 2026
Info: https://dktk.dkfz.de/forschung/joint-funding-programm/projekte/details/58/6751
BMBF Referenzhistologie für die GioVax-Studie - A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma
Laufzeit: 2019 - 2026
Info: Rapp M, Grauer OM, Kamp M, Sevens N, Zotz N, Sabel M, Sorg RV. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. Trials. 2018 May 25;19(1):293. doi: 10.1186/s13063-018-2659-7. PubMed
Deutsche Krebshife Referenzhistologie für die NOA-28/PRIDE-Studie - Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma
Laufzeit: 2024 - 2026
Info: https://www.journalonko.de/studien/details/pride-nct05871021